Menu Search
Equities

Ortoma AB

82Y:DEU

Ortoma AB

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ortoma AB is a Sweden-based company engaged in the medical technology. It develops an operation system for planning and positioning of joint implants in hip, knee and back surgery. The Company’s portfolio of products include Ortoma Treatment Solution, an integrated planning and measuring system, including a camera, navigation equipment and three-dimensional (3D) graphics for planning and performing prosthetic operations; Ortoma Plan, a preoperative planning system which allows surgeons to measure patient’s anatomy based on computer tomography or magnetic resonance, view it in 3D and plan operation and choice of implant before surgery; and Ortoma Guide, a navigation device which allows precise measurement and positioning of implants during operations. The Company cooperates with orthopedic departments at Sahlgrenska University Hospital, Skane University Hospital and Gothenburg University.

  • Revenue in SEK (TTM)42.58m
  • Net income in SEK-23.12m
  • Incorporated2001
  • Employees7.00
  • Location
    Ortoma ABFalkenbergsgatan 3 8TrGOETEBORG 41285SwedenSWE
  • Phone+46 317735163
  • Websitehttps://ortoma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.